Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

NCT05985655 is registered in ClinicalTrials.gov with Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05985655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05985655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 6, 2023
Completion date
May 31, 2028
Enrollment
230 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma (hnscc), hormone receptor positive [hr+] and human epidermal growth factor receptor 2 negative [her2-] breast carcinoma, non-small cell lung cancer (nsclc), pancreatic adenocarcinoma, platinum-resistant high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers (hgsoc), triple negative breast cancer (tnbc)